New PET tracer aims to light up tumors, but trial stalls

NCT ID NCT04168528

Terminated Diagnosis Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited information on its safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68GaNOTA-Anti-MMR-VHH2 (a radioactive imaging agent)
What this could lead to: If successful, this could provide a new way to see tumors on PET scans, helping doctors diagnose and monitor cancer more precisely.
What could go wrong: The trial was terminated early with only 13 participants, so we don't have enough data to know if it works safely. It was also an early-phase study, so many unknowns remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer HER2 positive breast carcinoma melanoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER MALIGNANT SOLID TUMOR MELANOMA (SKIN)

Contacts and locations

Locations

Uz Brussel

Brussels, Brussels Capital, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.